Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03208946
Other study ID # CIBIUG-P32-2016
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 6, 2017
Est. completion date February 15, 2018

Study information

Verified date June 2018
Source Universidad de Guanajuato
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effect of carboxymethyl-lysine (CML) on the levels of absorption and excretion of CML, and in the microbiota of healthy adults. To achieve the objective, a randomized clinical trial will be carried out. Before the intervention, subjects will have a washout period for seven days, then they will be randomly assigned to either a high-CML or to a low-CML diet for 5 days. Both groups will consume the foods provided by the researchers at the research center. Diets for this intervention will be based on an isocaloric diet that will include breakfast, lunch, snacks and dinner.

Blood samples will be taken the first day, the second day of the intervention, and after the five days of the intervention. Urine and fecal samples will be taken the day before the intervention and after the intervention. CML levels will be measured by Liquid chromatography tandem-mass spectrometry in serum and urine samples to evaluate the levels of absorption and excretion. DNA extraction from the fecal sample will be carried out by a commercial kit. Bacterial log10 number of copies will be determined by using q-PCR.


Description:

Advanced glycation end products (AGEs) are a heterogenous group of compounds form mainly by the Maillard reaction. AGEs can be found endogenously and in some foods. Several AGEs have been characterized, but carboxymethyl-lysine (CML) is one of the most widely studied in foods. Several studies have demonstrated the association between advanced glycation end products and several pathologies. However, few studies have focused on studying the absorption and excretion processes of these glycation products. Therefore, the objective of the study is to evaluate the effect of carboxymethyl-lysine (CML) on the levels of absorption and excretion of CML, and in the microbiota of healthy adults. To achieve the objective, a randomized clinical trial will be carried out, which will consist of a 7-day washout period during which participants will receive general recommendations that allow them to stick to a diet with a low CML content, adherence to these recommendations will be evaluated through three dietary records. At the end of the washing period, participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days. Participants will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention, these preparations will be elaborated by a catering company with indications and supervision by the research group. Participants will assist to the research center to receive the breakfast, lunch and snacks. After lunch the subjects will receive a package containing a snack for mid-evening and the dinner. Adherence to the diet during the intervention period will be evaluated through a dietary record of foods.

The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.

The diet with high content of CML will have twice the amount that the low diet, but with similar amounts of macro and micronutrients.

A blood sample will be taken on the first day of the intervention to measure CML basal levels. In order to evaluate the levels of CML absorption, the serum collection will be performed on the second day and at the end of the intervention. To evaluate the levels of CML excretion 24-hours urine will be collected the day before the intervention and the day after the dietary intervention finished. To evaluate the effects on the microbiota subjects will take a fecal sample the day before and a day after the intervention. Measurement of CML in serum, 24-hour urine and food will be performed by Liquid chromatography tandem-mass spectrometry. DNA extraction from the fecal sample will be carried out by a commercial kit. Bacterial log10 number of copies will be determined by using q-PCR.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 15, 2018
Est. primary completion date December 10, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 35 Years
Eligibility Inclusion Criteria:

- Adults 19 to 35 years old.

- Subjects with a body mass index (BMI) of 18.5 - 25 kg / m2

- Clinically healthy subjects, without presenting chronic diseases: diabetes mellitus, renal or cardiovascular disease.

- Non-smoking subjects.

- Subjects with low alcohol consumption.

- Subjects that do not consume food supplements.

- Subjects without known food allergies.

- Subjects without lactose intolerance or other foods.

- Subjects without gastrointestinal problems.

- Subjects who do not practice 150 minutes or more a week of physical exercise

Exclusion Criteria:

- Subjects with less than 80% adherence to the diet.

- Subjects who do not collect their indicated urine samples.

- Subjects presenting with an allergy, or adverse event during the intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High-CML diet
Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
Low-CML diet
Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.

Locations

Country Name City State
Mexico University of Guanajuato León Guanajuato

Sponsors (1)

Lead Sponsor Collaborator
Universidad de Guanajuato

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum levels of Carboxymethyl-lysine Changes in serum levels of Carboxymethyl-lysine, a marker of AGEs, will be measured. Carboxymethyl-lysine serum levels will be measured by Liquid chromatography tandem-mass spectrometry. six days
Primary Urinary levels of Carboxymethyl-lysine Changes in urinary levels of Carboxymethyl-lysine, a marker of AGEs, will be measured. Carboxymethyl-lysine urinary levels will be measured by Liquid chromatography tandem-mass spectrometry. six days
Secondary Bacterial log10 number of copies in fecal samples Changes in bacterial log10 number of copies in fecal sample will be measured by qPCR. six days
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1